Adagene locks in $69 mln Series D

Adagene Inc, an oncology immunotherapy company, has raised $69 million in Series D financing.

Adagene Inc, an oncology immunotherapy company, has raised $69 million in Series D financing. The lead backer was General Atlantic.

Source: Press Release